Business Context and Reporting Period
This Form 8-K Current Report was filed by SANUWAVE Health, Inc. on February 27, 2013, covering events occurring on February 21, 2013, and February 22, 2013. The filing primarily addresses the appointment of a new Chief Executive Officer and the closing of a debt financing round.
Key Financial Metrics and Capital Structure
- Debt Financing: The Company closed the initial sale of 18% Senior Secured Convertible Promissory Notes. The total offering size is up to $2,000,000, with an expected completion date of February 28, 2013.
- Note Terms: The Notes have a six-month term and a conversion price of $0.20 per share. They are secured by the Company's tangible and intangible assets.
- Conversion Mechanics: Upon a "qualified financing" or technology license of $4,000,000 or more, principal and interest automatically convert into common stock at the lower of a 20% discount to the new financing price or $0.20 per share.
- Executive Compensation: The new CEO, Joseph Chiarelli, has an annual base salary of $200,000 for the first year, increasing to $225,000 thereafter. He was granted options to purchase 2,250,000 shares at an exercise price of $0.35 per share.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins.
Material Changes and Corporate Actions
- Executive Appointment: Joseph Chiarelli was appointed Chief Executive Officer and a member of the Board of Directors, effective February 25, 2013. He replaces previous leadership to lead the Company.
- Capital Raise: The Company initiated a debt offering to raise up to $2,000,000 to fund operations and development.
- Equity Dilution Potential: The issuance of convertible notes and the grant of 2,250,000 stock options to the new CEO represent potential future dilution to existing shareholders.
Outlook, Risks, and Milestones
- Performance Milestones: The CEO's compensation includes cash bonuses tied to specific milestones:
- $35,000 for completing a financing of at least $5.0 million at a share price of not less than $0.35.
- $25,000 for enrolling the final patient in the dermaPACE Phase III clinical trial.
- $25,000 upon receipt of FDA approval for dermaPACE.
- $25,000 upon executing a license or distribution agreement generating at least $1.0 million in gross proceeds with $250,000 received.
- Option Vesting: CEO stock options vest based on the achievement of the same milestones listed above, with a significant portion (750,000 shares) vesting only if all milestones are met within the initial two-year term.
- Risks: The Company's ability to convert debt and achieve executive bonuses is contingent on securing significant future financing ($5.0 million) and regulatory approvals (FDA), which are not guaranteed.
Investor Verification Checklist
- Verify the total amount of the $2,000,000 Note offering actually subscribed and closed by February 28, 2013.
- Confirm the Company's current cash runway and whether the Note proceeds are sufficient to reach the next financing milestone.
- Review the status of the dermaPACE Phase III clinical trial and FDA approval timeline.
- Assess the impact of the 2,250,000 CEO options and potential note conversions on the fully diluted share count.
- Examine the full text of the Employment Agreement (Exhibit 10.1) and Note form (Exhibit 4.1) for additional covenants or restrictions.